Jim Greenwood Says BIO Welcomes Biosimilars; Clarity On Non-inferiority Trials For Substitutability Of Biotech Drugs May Come Up Next Year
This article was originally published in PharmAsia News
MUMBAI - The entry of biosimilars into the U.S. market will be welcomed by the biotech industry, Jim Greenwood, CEO of the Biotechnology Industry Organization, which represents multinational biotech companies, told the recent BioInvest conference in Mumbai
You may also be interested in...
BIO President Jim Greenwood Says Indian Biosimilars Welcome In U.S. Market: An Interview With PharmAsia News (Part 2 of 2)
WASHINGTON - BIO President Jim Greenwood recently returned from a trip across India aimed at drumming up interest in the BIO India Partnering Conference in September 2010; he touted India's burgeoning innovative biotech industry and discussed the growing interest of BIO in seeking new or expanded partnerships with Indian firms.